<DOC>
	<DOCNO>NCT03027544</DOCNO>
	<brief_summary>This clinical trial design investigate efficiency toxicity tomotherapy refractory brain metastasis .</brief_summary>
	<brief_title>Tomotherapy Refractory Brain Metastases</brief_title>
	<detailed_description>This single-arm , single center , phase II trial investigate feasibility toxicity tomotherapy refractory brain metastasis , define A : multiple brain metastasis ( ≥3 lesion ) ; B : large brain metastasis ( one lesion 's volume small 6cc long diameter shorter 3cm ) ; C : meningeal metastasis .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Histologic cytologic diagnosis primary tumor conform brain metastasis enhance MRI CT ; lesion number le 3 ; tumor volume small 6cc ; tumor diameter shorter 3cm ; uncontrolled brain tumor whole brain radiotherapy ( WBRT ) ; tumor adjacent essential structure brain , brain stem , optic chiasma , optic tract , etc ; KPS ≥60 , KPS ≥40 limitation motion simply cause brain tumor adjacent motor function area ; Age : 1875 year old ; Adequate endorgan function : WBC≥4.0x109/L Neu ≥ 1.5x109/L Hemoglobin ≥ 110 g/L Platelets ≥100 x109/L Total bilirubin ≤ 1.5x ULN AST ALT ≤ 1.5x ULN BUN Cr : within normal range . • Other clinically significant disease ( e.g.myocardial infarction within past 6 month , severe arrhythmia ) . Unable unwilling comply study protocol . The expected survival time le 3 month . Patients anticipated clinical trial brain metastasis . Patients treat SRT hospital Pregnant patient female patient whose HCG positive Unsuitable participate study , opinion treat physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>multiple brain metastasis</keyword>
	<keyword>large brain metastasis</keyword>
	<keyword>meningeal metastasis</keyword>
	<keyword>tomotherapy</keyword>
</DOC>